follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Eisai gets $65M for U.S. rights to Targretin

By

Back to Top Comments Email Print

Latest News

advertisement

Eisai Inc.’s U.S. operations announced today that it sold the U.S. rights to its Targretin capsules and gel to Montreal-based Valeant Pharmaceuticals International Inc.

Eisai, in Woodcliff Lake, received $65 million up front, plus potential future payments based on certain milestones. Valeant assumes responsibilities for all regulatory obligations associated with the product in the United States.

 

Share This Story On:

Write to the Editorial Department at editorial@njbiz.com

advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top